We are live on ! Find out more
COLL icon

Collegium Pharmaceutical

178 hedge funds and large institutions have $843M invested in Collegium Pharmaceutical in 2023 Q2 according to their latest regulatory filings, with 16 funds opening new positions, 63 increasing their positions, 70 reducing their positions, and 36 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding in top 10

Funds holding in top 10: 33 (0)

1.19% less ownership

Funds ownership: 114.62%113.43% (-1.2%)

10% less capital invested

Capital invested by funds: $936M → $843M (-$92.9M)

10% less repeat investments, than reductions

Existing positions increased: 63 | Existing positions reduced: 70

10% less funds holding

Funds holding: 198178 (-20)

56% less first-time investments, than exits

New positions opened: 16 | Existing positions closed: 36

91% less call options, than puts

Call options by funds: $122K | Put options by funds: $1.29M

Holders
178
Holders Change
-20
Holders Change %
-10.1%
% of All Funds
2.79%
Holding in Top 10
3
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.05%
New
16
Increased
63
Reduced
70
Closed
36
Calls
$122K
Puts
$1.29M
Net Calls
-$1.17M
Net Calls Change
+$1.8M
Name Holding Trade Value Shares
Change
Change in
Stake
Federated Hermes
51
Federated Hermes
Pennsylvania
$2.2M +$663K +29,223 +40%
TI
52
Trexquant Investment
Connecticut
$2.16M -$350K -15,428 -13%
AllianceBernstein
53
AllianceBernstein
Tennessee
$2.02M +$1.26M +55,600 +145%
Legal & General Group
54
Legal & General Group
United Kingdom
$2M +$291K +12,818 +16%
First Trust Advisors
55
First Trust Advisors
Illinois
$1.99M +$77.5K +3,414 +4%
CC
56
Clearline Capital
New York
$1.99M +$2.11M +92,744 New
N
57
Nuveen
North Carolina
$1.99M -$1.77M -77,833 -46%
HF
58
HRT Financial
New York
$1.7M +$318K +14,015 +22%
Connor, Clark & Lunn Investment Management (CC&L)
59
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$1.69M +$835K +36,799 +88%
Citadel Advisors
60
Citadel Advisors
Florida
$1.64M -$2.49M -109,820 -59%
Los Angeles Capital Management
61
Los Angeles Capital Management
California
$1.64M +$114K +5,023 +7%
Swiss National Bank
62
Swiss National Bank
Switzerland
$1.62M +$145K +6,400 +9%
Public Sector Pension Investment Board (PSP Investments)
63
Public Sector Pension Investment Board (PSP Investments)
Quebec, Canada
$1.33M +$61.2K +2,694 +5%
Fisher Asset Management
64
Fisher Asset Management
Washington
$1.26M
Prudential Financial
65
Prudential Financial
New Jersey
$1.07M +$384K +16,919 +51%
EIP
66
Easterly Investment Partners
Massachusetts
$1.07M +$559K +24,622 +98%
AA
67
AlphaCentric Advisors
Puerto Rico
$1.06M
AQR Capital Management
68
AQR Capital Management
Connecticut
$1.06M +$770K +33,912 +220%
AFAS
69
Acorn Financial Advisory Services
Virginia
$1.03M -$41.5K -1,826 -4%
GC
70
Globeflex Capital
California
$977K -$40.5K -1,783 -4%
CAPTRUST Financial Advisors
71
CAPTRUST Financial Advisors
North Carolina
$974K +$1.03M +45,327 New
JF
72
Jump Financial
Illinois
$937K -$259K -11,405 -21%
Man Group
73
Man Group
United Kingdom
$926K +$979K +43,100 New
California State Teachers Retirement System (CalSTRS)
74
California State Teachers Retirement System (CalSTRS)
California
$902K +$32.6K +1,438 +4%
CS
75
Credit Suisse
Switzerland
$877K +$29.7K +1,309 +3%

COLL Hedge Fund Activity: Q2 2023 in Review

178 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Collegium Pharmaceutical (COLL) for Q2 2023, worth a combined $843M — down 9.9% from $936M a quarter earlier.

Sellers outnumbered buyers: 36 funds closed out of COLL and 16 opened new positions — a net loss of 20 holders — while 70 trimmed existing stakes and 63 added.

The largest buyer was Victory Capital Management, adding an estimated $15.5M. The largest seller was Cambridge Investment Research Advisors, cutting an estimated $6.9M.

  • 178 institutional investors held Collegium Pharmaceutical (COLL) as of Q2 2023, down from 198 in Q1 2023.
  • Funds reported $843M of Collegium Pharmaceutical stock for Q2 2023, down 9.9% quarter-over-quarter.
  • 16 funds opened new Collegium Pharmaceutical positions in Q2 2023 and 36 closed out, a net change of -20 holders.
  • The largest Collegium Pharmaceutical buyer in Q2 2023 was Victory Capital Management, an estimated $15.5M added.
  • The largest Collegium Pharmaceutical seller in Q2 2023 was Cambridge Investment Research Advisors, an estimated $6.9M sold.

Based on aggregated 13F filings for Q2 2023.